Position in PHVS
as of Jun 30, 2026
· filed Aug 5, 2026
Position Value
$470,115
New position
Shares Held
13,595
first reported quarter
Ownership
0.019%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#89
of 124 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 0%
Shared 0%
None 100%
Position in Biotechnology
Healthcare · as of Jun 30, 2026OpenArc Corporate Advisory, LLC holds $10,123,972 across 17 Biotechnology names. PHVS ranks #6 (4.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TVTX |
Travere Therapeutics, Inc.
|
37,500 | $2,130,375 | |
| 2 | HALO |
Halozyme Therapeutics, Inc.
|
20,310 | $1,589,663 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
2,397 | $1,190,661 | |
| 4 | ARQT |
Arcutis Biotherapeutics, Inc.
|
30,700 | $804,954 | |
| 5 | PBYI |
Puma Biotechnology, Inc.
|
59,491 | $482,472 | |
| 6 | PHVS |
Pharvaris N.V.
This page
|
13,595 | $470,115 | |
| 7 | ARGX |
Argenx SE
|
500 | $463,885 | |
| 8 | REGN |
Regeneron Pharmaceuticals, Inc.
|
688 | $428,995 |
All Filings in PHVS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $470,115 | 13,595 | Shares | Sole | 2026-08-05 | |
| No filing history on record for this holder in this stock. | ||||||